

PRESS RELEASE

BELANO medical Boosts Distribution of Microbiome Products

Agreement reached to collaborate with b.value AG and DBI going forward

Düsseldorf / Berlin, 17 September 2020 – BELANO medical AG will team up with b.value AG, headquartered in Düsseldorf, and Deutsche Biotech Innovativ AG (DBI), which is based in Hennigsdorf bei Berlin, in the future development and distribution of microbiological and microbial ingredients for medical products and microbiome products. As part of this agreement, both companies have acquired shares in BELANO medical.

The collaboration is geared towards launching new, microbiome-based ingredients in the shape of finished medical products. Currently, one key aspect is the distribution of an ingredient for medical microbiotic skincare researched and developed by BELANO medical (“ibiotics” and “ibiotics med”). Also envisaged is extending the collaboration to other business units, including development of ingredients and solutions for ear, nose, and throat (ENT) diseases or gastrointestinal infections, e.g. by the bacterium *helicobacter pylori*.

“We are very much looking forward to supporting BELANO medical AG on its way to becoming the leading supplier of microbiotic products”, said Dr Georg Lentzen, member of b.value AG’s managing board. “We feel that BELANO’s microbiome paradigm offers great potential for innovative skincare and health products with a natural mechanism of action already proven in a wide range of studies.” b.value AG is an investment and joint venture company in industrial biotechnology, specialised in non-pharmaceutical biotechnology and chemistry in Germany, Austria, and Switzerland.

“DBI and b.value both provide extensive expertise in the R&D of medical products, this is very important for us”, explains Dr Christine Lang, professor for microbiology and board member for R&D at BELANO medical AG. All three companies are firmly established players in the biotechnology industry.

BELANO medical collaborates already with tradichem, a Spanish active ingredient manufacturer, in the international distribution of “salvans”, a patented lactobacillus developed by BELANO. The agent has a natural, non-antibiotic mechanism of action against the inflammatory pathogen *streptococcus pyogenes*. In August 2020, “salvans” was launched in Germany as a medical product (salvans throat lozenges) for use in prophylaxis and treatment.

About BELANO medical AG:

BELANO medical AG is a biotechnology company which leverages the findings of its research into beneficial microorganisms for its pharmaceutical and care products. The company develops and brings to market novel approaches to skin care, disease prevention, and the support of healing processes. In this way, new therapeutic options are created for indications which currently cannot be treated satisfactorily. BELANO's mission is to make its patented agents and products available to everyone. To do so, the company relies on national and international collaboration with distributors and larger partners.

For further Information:

BELANO medical AG
Neuendorfstraße 19
D-16761 Hennigsdorf (Berlin), Germany
Phone: +49 (0)3302 86 37 995
info@belanomedical.com
www.belanomedical.com